For Referring Physicians
For Referring Physicians
Refer your cardiology patients to trials at Amavita Research without losing continuity of care.
If you're a cardiologist, internist, or primary care physician with patients who might benefit from a cardiovascular clinical trial, Amavita Research works with you — not around you. Your patients remain yours for routine care. We coordinate trial-related visits, share progress with you on a schedule you choose, and return your patients to your practice when the trial ends. This page outlines our referral process, communication standards, and how we handle the practical details of multi-physician patient care.
Why refer to Amavita Research?
- Continuity of care preserved: Your patient stays your patient. We don't compete for their general cardiology care.
- Trial enrollment your patient might benefit from: Active trials in hypertension, heart failure, ACS, PAD, iron deficiency in HF, and other cardiovascular indications.
- Named PI accountability: Practicing cardiologists (Dr. Pedro Martinez-Clark, MD, FACC; Dr. Hans C. Rutzen-Lopez, MD; consultative input from Dr. William W. O'Neill, MD, FACC) — not part-time researchers.
- No financial conflict: We do not pay referral fees, and we do not require any financial arrangement with referring physicians. Your patient's interest is the only consideration.
- Communication on your terms: You decide what trial-related information you want, in what format, on what cadence.
How the referral process works
- Identify a potentially eligible patient. You see a patient in routine care whose condition might fit one of our active trials (see /trials for the current list). The decision to refer is entirely yours.
- Initial outreach. Contact us in whatever way is easiest — email research@amavita.health, call (786) 703-5941. Send only the minimum information needed: indication, age range, key clinical context. No PHI required at this stage unless you have patient authorization.
- Eligibility pre-check. Within 1-2 business days, we let you know whether the patient might be eligible for an active or upcoming trial. If yes, we coordinate the next step. If no, we explain why and (if appropriate) suggest other resources.
- Patient introduction (with your authorization). If you'd like, we contact the patient directly (with your written authorization) to schedule a screening visit. Or you can give the patient our information and let them reach out at their own pace.
- Screening and consent. At the screening visit, the patient meets our trial team, receives the informed consent form, and has time to decide. They can call you at any point during this process.
- Trial enrollment and ongoing care. If the patient enrolls, we run the trial visits per protocol. Your patient continues seeing you for routine cardiology care. We coordinate around your visit schedule when possible.
- Communication during the trial. We send you a brief progress note after key milestones (consent signed, randomization, dose changes, adverse events that affect their broader care) — formatted however you prefer.
- Trial completion and patient hand-back. When the patient completes the trial (or withdraws), we send you a closeout summary and the patient returns to your practice's normal care schedule.
What we communicate, and when
| Event | What we send | When |
|---|---|---|
| Eligibility pre-check response | Email confirming whether patient may be eligible | 1-2 business days from your inquiry |
| Consent signed | Brief note confirming enrollment and trial assignment | Within 1 business day of signing |
| Randomization | Brief note confirming patient's randomized arm (if blinded, what we can share) | Within 1 business day |
| Adverse event affecting broader care | Detailed clinical note with adverse-event grading and management plan | Same day, in time-critical situations within hours |
| Periodic progress (configurable) | Brief progress note per visit, or monthly summary | Per your preference |
| Trial completion or withdrawal | Closeout summary including final assessments and any follow-up plan | Within 5 business days of trial completion |
What we never do
- We never compete with you for your patient's general cardiology care
- We never share your patient's data with sponsors beyond what's required for the trial
- We never recommend your patient change their general cardiologist
- We never communicate with your patient in ways that bypass you when you've asked to be the primary communicator
- We never pay you referral fees, and we ask that you don't expect them
For your patient, before they see us
If you'd like to give your patient information before they contact us, the most useful patient-facing resources on our site are:
- /blog/what-to-expect-cardiovascular-clinical-trial — overall patient guide
- /blog/how-to-read-a-clinical-trial-consent-form — practical guide to the consent process
- /trials — list of active trials by indication and PI
- /clinical-trial-glossary — definitions of clinical trial terms
You can hand-print any of these for your patients or send them the URL.
Working with us at scale
For cardiology groups, primary care practices, and large medical groups in South Florida considering an ongoing referral relationship, we can set up a streamlined process: a designated point of contact in your practice, a shared eligibility pre-check workflow, and a regular cadence of communication. Email research@amavita.health with the subject line "practice referral inquiry" to discuss.
Contact
- Email: research@amavita.health
- Phone: (786) 703-5941
- Address: 100 NW 170 Street, Suite 305, North Miami Beach, FL 33169
- For protocol questions: Email Dr. Pedro Martinez-Clark via /contact-sponsor